Kelfiprim versus co-trimoxazole in recurrent and persistent urinary tract infections: multicenter double-blind trial

G. Graziani, G. Pincella, C. Chiarini, F. Piaia, D. Limido, P. Zucchelli, A. Cantaluppi, F. Locatelli, P. Marai, C. Ponticelli

Research output: Contribution to journalArticle

Abstract

Kelfiprim (KP) is a new bactericidal agent containing trimethoprim (T) and sulfametopyrazine (S), a long-acting sulfonamide (ratio 5:4). The posology is one capsule (T 250 mg + S 200 mg) daily, after a loading dose of two capsules on the first day. To evaluate the clinical value of Kelfiprim (KP) vs co-trimoxazole (CO) in urinary tract infection (UTI) a controlled multicenter double-blind trial (MDBT) was carried out in 76 patients suffering from persistent and recurrent UTIs. About 90 per cent response rate (sterile urine at the end of treatment) was obtained for KP and about 85 per cent for CO in recurrent UTI. In persistent UTI the rate of recovery was 66.8 per cent and 53 per cent for KP and CO, respectively. Safety of treatments was excellent in 97 per cent of patients treated with Kelfiprim and 87 per cent treated with co-trimoxazole. Two patients, one in each group, were dropped from the study because of adverse reactions.

Original languageEnglish
Pages (from-to)293-297
Number of pages5
JournalUrology
Volume30
Issue number3
DOIs
Publication statusPublished - 1987

Fingerprint

Sulfamethoxazole Drug Combination Trimethoprim
Urinary Tract Infections
Carbon Monoxide
Capsules
Sulfalene
Trimethoprim
Sulfonamides
kelfiprim
Urine
Safety
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Kelfiprim versus co-trimoxazole in recurrent and persistent urinary tract infections : multicenter double-blind trial. / Graziani, G.; Pincella, G.; Chiarini, C.; Piaia, F.; Limido, D.; Zucchelli, P.; Cantaluppi, A.; Locatelli, F.; Marai, P.; Ponticelli, C.

In: Urology, Vol. 30, No. 3, 1987, p. 293-297.

Research output: Contribution to journalArticle

Graziani, G, Pincella, G, Chiarini, C, Piaia, F, Limido, D, Zucchelli, P, Cantaluppi, A, Locatelli, F, Marai, P & Ponticelli, C 1987, 'Kelfiprim versus co-trimoxazole in recurrent and persistent urinary tract infections: multicenter double-blind trial', Urology, vol. 30, no. 3, pp. 293-297. https://doi.org/10.1016/0090-4295(87)90262-7
Graziani, G. ; Pincella, G. ; Chiarini, C. ; Piaia, F. ; Limido, D. ; Zucchelli, P. ; Cantaluppi, A. ; Locatelli, F. ; Marai, P. ; Ponticelli, C. / Kelfiprim versus co-trimoxazole in recurrent and persistent urinary tract infections : multicenter double-blind trial. In: Urology. 1987 ; Vol. 30, No. 3. pp. 293-297.
@article{65f03d31e2eb4332bfeac7be244b4ae4,
title = "Kelfiprim versus co-trimoxazole in recurrent and persistent urinary tract infections: multicenter double-blind trial",
abstract = "Kelfiprim (KP) is a new bactericidal agent containing trimethoprim (T) and sulfametopyrazine (S), a long-acting sulfonamide (ratio 5:4). The posology is one capsule (T 250 mg + S 200 mg) daily, after a loading dose of two capsules on the first day. To evaluate the clinical value of Kelfiprim (KP) vs co-trimoxazole (CO) in urinary tract infection (UTI) a controlled multicenter double-blind trial (MDBT) was carried out in 76 patients suffering from persistent and recurrent UTIs. About 90 per cent response rate (sterile urine at the end of treatment) was obtained for KP and about 85 per cent for CO in recurrent UTI. In persistent UTI the rate of recovery was 66.8 per cent and 53 per cent for KP and CO, respectively. Safety of treatments was excellent in 97 per cent of patients treated with Kelfiprim and 87 per cent treated with co-trimoxazole. Two patients, one in each group, were dropped from the study because of adverse reactions.",
author = "G. Graziani and G. Pincella and C. Chiarini and F. Piaia and D. Limido and P. Zucchelli and A. Cantaluppi and F. Locatelli and P. Marai and C. Ponticelli",
year = "1987",
doi = "10.1016/0090-4295(87)90262-7",
language = "English",
volume = "30",
pages = "293--297",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Kelfiprim versus co-trimoxazole in recurrent and persistent urinary tract infections

T2 - multicenter double-blind trial

AU - Graziani, G.

AU - Pincella, G.

AU - Chiarini, C.

AU - Piaia, F.

AU - Limido, D.

AU - Zucchelli, P.

AU - Cantaluppi, A.

AU - Locatelli, F.

AU - Marai, P.

AU - Ponticelli, C.

PY - 1987

Y1 - 1987

N2 - Kelfiprim (KP) is a new bactericidal agent containing trimethoprim (T) and sulfametopyrazine (S), a long-acting sulfonamide (ratio 5:4). The posology is one capsule (T 250 mg + S 200 mg) daily, after a loading dose of two capsules on the first day. To evaluate the clinical value of Kelfiprim (KP) vs co-trimoxazole (CO) in urinary tract infection (UTI) a controlled multicenter double-blind trial (MDBT) was carried out in 76 patients suffering from persistent and recurrent UTIs. About 90 per cent response rate (sterile urine at the end of treatment) was obtained for KP and about 85 per cent for CO in recurrent UTI. In persistent UTI the rate of recovery was 66.8 per cent and 53 per cent for KP and CO, respectively. Safety of treatments was excellent in 97 per cent of patients treated with Kelfiprim and 87 per cent treated with co-trimoxazole. Two patients, one in each group, were dropped from the study because of adverse reactions.

AB - Kelfiprim (KP) is a new bactericidal agent containing trimethoprim (T) and sulfametopyrazine (S), a long-acting sulfonamide (ratio 5:4). The posology is one capsule (T 250 mg + S 200 mg) daily, after a loading dose of two capsules on the first day. To evaluate the clinical value of Kelfiprim (KP) vs co-trimoxazole (CO) in urinary tract infection (UTI) a controlled multicenter double-blind trial (MDBT) was carried out in 76 patients suffering from persistent and recurrent UTIs. About 90 per cent response rate (sterile urine at the end of treatment) was obtained for KP and about 85 per cent for CO in recurrent UTI. In persistent UTI the rate of recovery was 66.8 per cent and 53 per cent for KP and CO, respectively. Safety of treatments was excellent in 97 per cent of patients treated with Kelfiprim and 87 per cent treated with co-trimoxazole. Two patients, one in each group, were dropped from the study because of adverse reactions.

UR - http://www.scopus.com/inward/record.url?scp=0023620021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023620021&partnerID=8YFLogxK

U2 - 10.1016/0090-4295(87)90262-7

DO - 10.1016/0090-4295(87)90262-7

M3 - Article

C2 - 3307097

AN - SCOPUS:0023620021

VL - 30

SP - 293

EP - 297

JO - Urology

JF - Urology

SN - 0090-4295

IS - 3

ER -